pantoprazole + bismuth + metronidazole + tetracycline
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Helicobacter Infection
Conditions
Helicobacter Infection
Trial Timeline
Jun 1, 2008 → Nov 1, 2010
NCT ID
NCT00841854About pantoprazole + bismuth + metronidazole + tetracycline
pantoprazole + bismuth + metronidazole + tetracycline is a approved stage product being developed by Pacific Biosciences for Helicobacter Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00841854. Target conditions include Helicobacter Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00841854 | Approved | Completed |
Competing Products
6 competing products in Helicobacter Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy | Sun Pharmaceutical | Approved | 85 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| helicobacter pylori vaccine + helicobacter pylori vaccine + helicobacter pylori vaccine + helicobacter pylori vaccine + Placebo + helicobacter pylori vaccine + helicobacter pylori vaccine | Novartis | Phase 1 | 33 |
| H.pylori vaccines + Placebo Vaccine | Novartis | Phase 1 | 33 |
| Vonoprazan + Amoxicillin + Clarithromycin + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 72 |
| RHB-105 + Active Comparator | RedHill Biopharma | Phase 3 | 69 |